News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Durata Therapeutics, Inc.  (DRTX) Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Findings at IDWeek 2013™



10/2/2013 9:42:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced a comprehensive review of the efficacy, safety and microbiology data of the company's lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). The data is being presented in six posters at this year's IDWeek 2013™, held in San Francisco, Calif., October 2-6, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES